We are live on ! Find out more
SAGE

Sage Therapeutics
SAGE

Delisted

SAGE was delisted on the 30th of July, 2025.

Back to rankings

143 hedge funds and large institutions have $927M invested in Sage Therapeutics in 2016 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 72 increasing their positions, 27 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 27

71% more call options, than puts

Call options by funds: $3.63M | Put options by funds: $2.12M

67% more funds holding in top 10

Funds holding in top 10: 6 → 10 (+4)

38% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 21

4% more funds holding

Funds holding: 137 → 143 (+6)

32% less capital invested

Capital invested by funds: $1.37B → $927M (-$440M)

Holders
143
Holders Change
+6
Holders Change %
+4.38%
% of All Funds
3.81%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.27%
New
29
Increased
72
Reduced
27
Closed
21
Calls
$3.63M
Puts
$2.12M
Net Calls
+$1.51M
Net Calls Change
+$3.24M

Top Buyers

1
O
OppenheimerFunds
New York
+$26.4M
2
CAM
Cormorant Asset Management
Massachusetts
+$22.2M
3
DM
Deerfield Management
New York
+$18.1M
4
VAM
Visium Asset Management
New York
+$17.1M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$16.5M

Top Sellers

1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$19.8M
2
HCMT
Highland Capital Management (Texas)
Texas
-$8.92M
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$7.7M
4
OAM
Oxford Asset Management
United Kingdom
-$6.75M
5
GGHC
Gilder Gagnon Howe & Co
New York
-$5.67M
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$9.44M +$8.99M +255,293 +650%
Federated Hermes
27
Federated Hermes
Pennsylvania
$7.86M +$1.41M +40,000 +20%
BBA
28
Baker Bros. Advisors
New York
$7.18M +$4.19M +119,048 +113%
PHS
29
PFM Health Sciences
California
$6.35M +$5.53M +157,208 +385%
CC
30
Casdin Capital
New York
$6.06M +$1.62M +45,989 +32%
Norges Bank
31
Norges Bank
Norway
$5.95M +$2.29M +65,000 +54%
Northern Trust
32
Northern Trust
Illinois
$5.84M +$1.07M +30,538 +20%
EAM
33
Eventide Asset Management
Massachusetts
$5.45M +$1.55M +44,100 +35%
OM
34
Opaleye Management
Massachusetts
$5.29M +$2.29M +65,000 +65%
GTC
35
Ghost Tree Capital
New York
$5.13M -$1.41M -40,000 -20%
PC
36
Polar Capital
United Kingdom
$5.13M +$5.63M +160,000 New
TCM
37
Tekla Capital Management
Massachusetts
$4.71M +$1.72M +49,000 +50%
NLVP
38
New Leaf Venture Partners
New York
$4.57M +$5.02M +142,570 New
SFM
39
Sphera Funds Management
Israel
$3.94M +$1.06M +30,000 +32%
BA
40
BlackRock Advisors
Delaware
$3.86M +$67.8K +1,926 +2%
CGL
41
Clarius Group LLC
Washington
$3.56M +$3.91M +110,950 New
HP
42
Harbourvest Partners
Massachusetts
$3.35M – – –
JGC
43
J. Goldman & Co
New York
$3.27M +$3.59M +102,000 New
SM
44
Sabby Management
Florida
$3.21M +$3.23M +91,877 +1,131%
Bank of New York Mellon
45
Bank of New York Mellon
New York
$2.95M -$7.7M -218,795 -70%
UBS AM
46
UBS AM
Illinois
$2.85M -$141K -3,999 -4%
GH
47
GAM Holding
Switzerland
$2.55M – – –
Goldman Sachs
48
Goldman Sachs
New York
$2.54M +$1.67M +47,413 +149%
Alyeska Investment Group
49
Alyeska Investment Group
Illinois
$2.53M +$2.78M +78,917 New
AP
50
AlpInvest Partners
Netherlands
$2.52M – – –
1
2
3 4 5

SAGE Hedge Fund Activity: Q1 2016 in Review

143 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q1 2016, worth a combined $927M — down 32% from $1.37B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new SAGE positions and 21 closed out — a net gain of 8 holders — while 72 added to existing stakes and 27 trimmed.

The largest buyer was OppenheimerFunds, opening a new position worth an estimated $26.4M. The largest seller was Lord, Abbett & Co, cutting an estimated $19.8M.

  • 143 institutional investors held Sage Therapeutics (SAGE) as of Q1 2016, up from 137 in Q4 2015.
  • Funds reported $927M of Sage Therapeutics stock for Q1 2016, down 32% quarter-over-quarter.
  • 29 funds opened new Sage Therapeutics positions in Q1 2016 and 21 closed out, a net change of +8 holders.
  • The largest Sage Therapeutics buyer in Q1 2016 was OppenheimerFunds, an estimated $26.4M added.
  • The largest Sage Therapeutics seller in Q1 2016 was Lord, Abbett & Co, an estimated $19.8M sold.

Based on aggregated 13F filings for Q1 2016.